BioLife Solutions, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US09062W2044
USD
26.04
0.46 (1.8%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
BioLife Solutions, Inc.
Artivion, Inc.
Silk Road Medical, Inc.
OrthoPediatrics Corp.
Treace Medical Concepts, Inc.
The Beauty Health Co.
Atrion Corp.
Cytek Biosciences, Inc.
Varex Imaging Corp.
Embecta Corp.
Nevro Corp.

Why is BioLife Solutions, Inc. ?

1
With a growth in Net Sales of 46.39%, the company declared Outstanding results in Mar 26
  • The company has declared positive results for the last 3 consecutive quarters
  • OPERATING CASH FLOW(Y) Highest at USD 17.9 MM
  • ROCE(HY) Highest at -2.9%
  • PRE-TAX PROFIT(Q) At USD 1.25 MM has Grown at 141.32%
2
High Institutional Holdings at 100%
  • These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to BioLife Solutions, Inc. should be less than 10%
  2. Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is BioLife Solutions, Inc. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
BioLife Solutions, Inc.
21.0%
0.47
44.93%
S&P 500
25.41%
1.92
13.25%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
14.88%
EBIT Growth (5y)
-224.57%
EBIT to Interest (avg)
-24.47
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.28
Tax Ratio
1.27%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.41
EV to EBIT
-49.16
EV to EBITDA
-68.50
EV to Capital Employed
2.81
EV to Sales
8.48
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-5.72%
ROE (Latest)
-3.26%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

23What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD 17.9 MM

ROCE(HY)

Highest at -2.9%

PRE-TAX PROFIT(Q)

At USD 1.25 MM has Grown at 141.32%

NET PROFIT(Q)

At USD 1.19 MM has Grown at 139.11%

DEBT-EQUITY RATIO (HY)

Lowest at -17.77 %

DEBTORS TURNOVER RATIO(HY)

Highest at 8.98 times

EPS(Q)

Highest at USD 0.02

-1What is not working for the Company
RAW MATERIAL COST(Y)

Grown by 5.32% (YoY

Here's what is working for BioLife Solutions, Inc.

Operating Cash Flow
Highest at USD 17.9 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit
At USD 1.25 MM has Grown at 141.32%
over average net sales of the previous four periods of USD -3.02 MM
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 1.19 MM has Grown at 139.11%
over average net sales of the previous four periods of USD -3.03 MM
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

EPS
Highest at USD 0.02
in the last five periods
MOJO Watch
Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Debt-Equity Ratio
Lowest at -17.77 %
in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Debtors Turnover Ratio
Highest at 8.98 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Here's what is not working for BioLife Solutions, Inc.

Raw Material Cost
Grown by 5.32% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales